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• The	clinical	urgency	 should	be	made	available	 to	 the	 individual	performing	 the	
related	and	unrelated	donor	search	(Grade	1B)	
• HLA	 high	 resolution	 typing	 should	 be	 performed	 on	 potential	 matching;	
mismatching	and	haploidentical	related	donors	when	familial	haplotypes	cannot	
be	fully	assigned	(Grade	1A)	








• Where	 a	 10/10	matched	 PBSC	 or	 bone	marrow	donor	 is	 not	 available	 a	 single	
mismatch	at	HLA-A,	-B,	-C,	-DRB1	or	–DQB1	is	acceptable	(Grade	1A).	
• Alternative	 progenitor	 cell	 donors	 (cord	 blood	 or	 haplo-identical)	 should	 be	
considered	early	 in	the	donor	search	when	a	patient	 is	unlikely	to	have	an	HLA	
matched	unrelated	donor	(Grade	1A).	










• For	 mismatched	 related	 and	 unrelated	 donor	 selection,	 HVG	 mismatches	 are	
favoured	over	bi-directional	and	GVH	mismatches	(Grade	2C).	




• HLA	 alloantibody	 testing	 of	 the	 recipient	 should	 be	 performed	 at	 the	 time	 of	
donor	search	and	should	be	repeated	at	the	time	of	donor	work-up	request	if	an	
HLA	mismatched	donor	is	selected	(Grade	1A).	
• The	clinical	 team	must	be	made	aware	of	any	HLA	alloantibody	 incompatibility	
for	a	selected	donor	(Grade	1A).		
• When	 a	 choice	 of	 equally	well	matched	 donors	 is	 available,	 avoid	 selection	 of	
donors	against	which	the	patient	has	HLA	alloantibodies	(Grade	1A).	
• HLA	alloantibody	 testing	 should	be	performed	 in	 cases	of	 failed	engraftment	 if	
the	donor	is	HLA	mismatched	(Grade	1B).	
• The	 guideline	 published	 by	 Emery	 et	 al.,	 2013	 recommending	 CMV	 matching	
between	patient	and	donor	should	be	followed	(Grade	1A).	






















i) A	 writing	 committee	 (authors	 of	 this	 manuscript)	 comprising	
Histocompatibility	 and	 Immunogenetics	 (H&I)	 scientists	 providing	 an	 H&I	
clinical	 service	 for	 related	 and	 unrelated	 donor	 haematopoietic	 progenitor	
cell	 transplantation	 was	 established.	 The	 chair	 of	 the	 committee,	 Ann-
Margaret	Little	was	appointed.	
ii) A	search	of	peer-reviewed	literature	to	June	31st	2015	was	undertaken	
iii) Recommendations	 were	 produced	 from	 evidence	 obtained	 from	 the	
literature	search.	Due	to	the	specialist	nature	of	histocompatibility	testing	in	
the	 context	 of	 haematopoietic	 progenitor	 cell	 allotransplantation	 there	 are	
few	large	and/or	multicentre	studies	 in	this	field	and	meta-analyses	are	not	
available.	 Some	 recommendations	 are	based	on	both	 literature	 review	and	
consensus	of	expert	opinion.	
iv) The	GRADE	nomenclature	was	used	to	evaluate	the	impact	of	evidence	and	





















attest	 to	 the	 accuracy,	 completeness	 or	 currency	 of	 the	 opinions	 and	 information	







The	 infusion	 (transplantation)	 of	 haematopoietic	 progenitor	 stem	 cells	 (HPC)	 into	 a	
patient	with	haematological	failure	due	to	malignant	or	non-malignant	causes	can	result	
in	successful	engraftment	of	donor	derived	HPC	which	undergo	haemopoiesis	to	replace	
the	malfunctioning	 cells	 of	 the	 patient’s	 immune	 system.	 HPC	 transplantation	 is	 also	
referred	to	as	bone	marrow	transplantation	(as	the	HPCs	may	be	taken	from	the	bone	
marrow	 of	 the	 donor)	 and	 stem	 cell	 transplantation.	 HPC	 transplants	 have	 been	
successfully	 performed	 since	 the	 late	 1960s.	 The	 effectiveness	 of	 these	 transplants	 in	
terms	 of	 patient	 overall	 survival	 and	 disease	 free	 survival	 has	 improved	 with	 each	
decade	due	to	more	accurate	histocompatibility	matching	between	donor	and	patient;	
















Amongst	 the	 many	 factors	 that	 contribute	 to	 successful	 transplantation,	 the	 most	
significant	is	the	degree	of	histocompatibility	between	donor	and	patient.	Compatibility	






proteins)	which	are	 found	on	 the	 surface	of	all	nucleated	cells	 and	platelets,	 and	HLA	
class	II	(including	HLA-DR,	HLA-DQ	and	HLA-DP	proteins)	which	are	normally	expressed	
on	 cells	 involved	 in	 antigen	 presentation	 such	 as	 dendritic	 cells	 and	 B-cells.	 The	
expression	of	HLA	class	 II	molecules	can	be	 induced	on	other	cell	 types	such	as	T-cells	
following	activation.	HLA	proteins	play	an	important	role	in	the	development	of	immune	
responses	against	non-self	antigens.	These	non-self	antigens	are	derived	 from	viruses;	
bacteria;	 abnormal	 proteins	 expressed	 by	 malignant	 cells	 and	 also	 non-self	 proteins,	
including	 HLA	 proteins	 expressed	 on	 transplanted	 cells	 and	 organs.	 Peptides	 derived	









The	 genes	 encoding	 HLA	 proteins	 are	 located	 on	 the	 short	 arm	 of	 chromosome	 six	
within	 a	 gene	 dense	 region	 of	 the	 genome	 entitled	 the	 Major	 Histocompatibility	
Complex	 (MHC),	 so	 named	 due	 to	 the	 role	 the	 genes	 found	 in	 this	 region	 have	 in	















and	 2xHLA-DP).	 Possessing	 multiple	 different	 HLA	 proteins	 that	 are	 able	 to	 interact	
individually	 with	 immune	 cells	 enables	 our	 immune	 systems	 to	 respond	 rapidly	 and	
effectively	to	unwanted	pathogens	and	malignant	changes.			At	the	population	level,	the	
existence	 of	multiple	 individuals	with	 different	 variants	 of	 HLA	 proteins	 increases	 the	
chances	that	an	individual	will	exist	with	a	functional	HLA	phenotype	able	to	initiate	an	
immune	 response	 against	 a	 particular	 pathogen.	 Therefore	multiple	 polymorphic	 HLA	
genes	 are	 essential	 for	 the	 immune	 system	 to	 be	 able	 to	 defend	 its	 host	 against	 a	
plethora	 of	 non-self	 antigens.	 However	 this	 polygenic	 and	 polymorphic	 HLA	 system	
confers	 a	 significant	 obstacle	 when	 cells	 from	 one	 individual	 are	 transplanted	 into	
another.		
	
In	 a	 HPC	 transplant	 alloreactive	 cells	 of	 the	 patient	 can	 initiate	 an	 immune	 response	
against	 non-self	 antigens	 expressed	 by	 the	 donor	 cells	 causing	 rejection	 of	 the	 donor	
cells	seen	clinically	as	failed	engraftment.	Pre-transplant	conditioning	of	the	patient	with	
chemotherapy	and/or	irradiation	reduces	this	host	versus	graft	(HVG)	response	allowing	
the	 donor	 cells	 to	 engraft.	 Conversely,	 immune	 reactive	 cells	 from	 the	 donor,	 can	
initiate	an	attack	against	non-self	antigens	expressed	by	tissues	of	the	recipient	causing	
a	 graft	 versus	 host	 (GVH)	 immune	 response.	 This	 ‘acute	 Graft	 versus	 Host	 Disease’	
(aGVHD)	 is	 graded	 from	 I	 to	 IV	 (mild	 to	 severe)	 and	 involves	 multiple	 organs	 of	 the	








The	 impact	of	matching	 the	HLA	alleles	of	patient	and	donor,	as	 is	 the	case	when	 the	
donor	 is	 an	 HLA	 matched	 sibling,	 contributes	 significantly	 to	 optimal	 outcome	 by	
reducing	the	alloreactions	that	contribute	to	HVG	and	GVHD	responses.		
	
Early	 data	 demonstrated	 better	 outcomes	 for	 patients	 receiving	 a	 transplant	 from	 an	
HLA	matched	 sibling	 donor	 compared	 to	 an	 unrelated	 donor.	 HLA	 typing	 to	 high	 and	
allele	level	resolution	has	resulted	in	improved	matching	between	unrelated	donors	and	
patients	leading	to	increased	survival	for	patients	receiving	unrelated	donor	transplants	
and	 giving	 comparable	 outcomes	 for	 some	 disease	 e.g.	 no	 effect	 of	 donor	 type	 on	
overall	 survival	 was	 observed	 in	 a	 cohort	 of	 108	 patients	 transplanted	 for	
haematological	 malignancies	 within	 a	 reduced	 intensity	 conditioning	 (RIC)	 regimen	
(Robin	et	al.,	2013).	An	earlier	study	comparing	transplant	outcomes	for	226	adult	acute	
myeloid	 leukaemia	 (AML)	 patients	 in	 first	 complete	 remission	 receiving	myeloablative	
unrelated	and	related	donor	transplants	during	1996-2007	demonstrated	the	probability	
of	 an	 unfavourable	 outcome	 in	 terms	 of	 overall	 survival,	 relapse	 and	 non	 relapse	
mortality	(NRM)	was	higher	for	patients	receiving	a	unrelated	donor	transplant	although	
not	 statistically	 significant,	 with	 patients	 receiving	 a	 9/10	 matched	 unrelated	 donor	
having	 similar	 outcomes	 to	 patients	 receiving	 a	 10/10	 matched	 unrelated	 donor	









HLA	 alloantibody	 status	 of	 a	 patient	 undergoing	 transplantation	 must	 be	 validated	
within	 the	 laboratory	 where	 it	 is	 used.	 Within	 the	 United	 Kingdom	 HLA	 typing	 and	
alloantibody	identification	for	HPC	transplantation	must	be	performed	according	to	the	
















HLA	 alleles	 can	 be	 identified	 to	 varying	 degrees	 of	 resolution	 depending	 on	 the	
methodology	and	interpretation	used.	The	definitions	for	low,	high	and	allele	resolution	
typing	 as	 compiled	 by	 a	 joint	 international	 working	 party:	 the	 Harmonisation	 of	
Histocompatibility	 Typing	 Terms	Working	 Group,	 to	 define	 a	 consensual	 language	 for	





The	 term	 intermediate	 resolution	 can	 be	 applied	 when	 high	 resolution	 cannot	 be	
achieved	and	the	provided	HLA	type	includes	a	subset	of	alleles	sharing	the	digits	in	the	
first	field	of	their	allele	name	and	excludes	some	alleles	sharing	those	digits	e.g.	A*02:01	
or	A*02:02	or	A*02:07	or	A*02:20	but	 not	 other	A*02	 alleles.	 There	may	be	 cases	 in	
which	the	subset	of	alleles	 includes	one	or	more	alleles	within	a	group	beginning	with	




Due	 to	 the	 variety	of	 assays	 available	 to	a	 clinical	H&I	 laboratory	and	 the	 variation	 in	
resolution	 of	 HLA	 typing	 results	 generated,	 a	 standard	 format	 for	 reporting	 is	
encouraged	to	ensure	that	data	can	be	communicated	between	 laboratories	and	their	





heterozygosity	 and	 haplotype	 assignments.	 When	 reporting	 high	 resolution	 results	
containing	ambiguous	allele	combinations,	all	ambiguities	must	be	stated	on	the	report,	
or	 alternatively	 a	 comment	 made	 that	 ambiguities	 have	 not	 been	 excluded	 and	 are	
available	 to	 the	 user	 upon	 request.	 It	 is	 necessary	 for	 laboratories	 performing	 HLA	
typing	 to	define	 the	 level	of	 resolution	typing	 that	 they	are	undertaking	e.g.	 reporting	
intermediate	 resolution	 results	 as	 high	 resolution	 is	 inaccurate	 and	 could	 lead	 to	 in	
appropriate	selection	of	optimum	donor	by	missing	rare	and	novel	alleles.	
	












One	 of	 the	 earliest	 steps	 in	 donor	 selection	 is	 to	 consider	 the	 disease	 status	 of	 the	
patient.	Patients	with	a	slowly	progressing	disease	such	as	a	myelodysplastic	syndrome	
(MDS)	 allocated	 to	 international	 prognostic	 score	 system	 (IPSS)	 risk	 groups	 low	 and	
intermediate-1	 will	 have	 time	 to	 allow	 a	 search	 for	 the	 best	 matched	 related	 or	
unrelated	donor.	 In	these	cases	delayed	transplantation	to	source	the	optimum	donor	
can	maximise	overall	 survival.	However,	 for	patients	with	acute	 leukaemias	where	 the	
patient’s	 condition	 can	 rapidly	 deteriorate,	 there	 may	 only	 be	 a	 limited	 window	 of	
opportunity	to	transplant	when	the	patient	is	in	clinical	remission,	thus	limiting	the	time	
available	 for	 an	 extended	 related	 or	 unrelated	 donor	 search	 (Cutler	 et	 al.,	 2004).	 A	
patient	progressing	to	an	advanced	disease	usually	has	a	higher	mortality	risk	from	the	
disease	 than	 the	 added	 risk	 of	 a	 transplant	 from	 a	 single	 allele	 mismatch	 donor	 or	





impact	 of	 the	 time	 required	 to	 identify	 an	 optimum	matching	 donor	 has	 to	 be	 offset	
against	 the	 potential	 negative	 impact	 of	 the	 disease	 stage	 and	 progression	 and	 will	
determine	the	source	of	progenitor	cells	 selected	 for	 treatment	 (Weisdorf	2008).	 	The	
transplant	 team	must	 advise	 the	H&I	 laboratory	on	 the	 stage	of	 the	patient’s	 disease	










The	 initial	 search	 for	 an	 HLA	 matched	 donor	 is	 usually	 within	 the	 patient’s	 family	
although	for	certain	genetic	diseases	a	related	donor	may	not	be	appropriate	if	they	are	
a	 carrier	of	 the	 same	genetic	mutation.	Although	 recent	 studies	 show	good	outcomes	
with	both	related	and	unrelated	donors	(Robin	et	al.,	2013)	there	is	still	an	advantage	in	
selecting	 a	 related	 donor	 over	 and	 above	 genetic	 compatibility.	 Related	 donors	 are	




There	 is	 a	 25%	 theoretical	 chance	 of	 finding	 an	 HLA	 identical	 sibling	 for	 a	 patient.	






data	 can	 usually	 be	 derived	 for	 paediatric	 patients	 but	 is	 rarely	 available	 for	 adult	





identification	 of	 sibling	 donors	 that	 are	 HLA	 matches,	 without	 having	 to	 perform	




parents)	 to	 identify	 potential	 matches,	 does	 not	 allow	 accurate	 determination	 of	
haplotypes	 and	 can	 lead	 to	 wrongly	 establishing	 presumptive	 matches.	 This	 is	 a	
particular	 concern	 when	 there	 is	 haplotype	 sharing	 between	 parents	 or	 apparent	










All	 potential	 recombination	 events	within	 the	 HLA	 region,	 identified	within	 a	 patient,	




A	 single	 HLA	 antigen	 or	 allele	 mismatched	 related	 donor	 may	 be	 identified	 within	 a	
family,	 due	 to	 the	 parents	 sharing	 a	 closely	 matched	 haplotype	 or	 in	 the	 infrequent	
occurrence	 of	 genetic	 recombination.	 This	 related	 donor	 could	 be	 an	 acceptable	
mismatched	 donor	 in	 the	 absence	 of	 a	 fully	 matched	 related	 donor.	 Comparison	 of	
outcome	data	for	patients	receiving	10/10	matched	unrelated	donor	transplants	versus	









If	 HLA	 mismatched	 related	 donors	 are	 selected,	 the	 degree	 of	 mismatching	 must	 be	
accurately	determined	by	performing	high	resolution	typing	for	HLA-A,	-B,	-C,	-DRB1	and	




A	 number	 of	 clinical	 protocols	 include	 the	 use	 of	 a	 single	 haplotype	 identical	 family	
member	 (haploidentical).	 This	 transplant	 format	 was	 pioneered	 by	 the	 Perugia	 and	
Frankfurt	groups	combined	with	a	‘megadose’	of	selected	stem	cells	(Aversa	et	al.,	2001	
and	Rizzieri	et	al.,	2007).	Current	protocols	include	the	post-transplant	administration	of	
cyclophosphamide	 to	 actively	 destroy	 proliferating	 alloreactive	 lymphocytes	 thus	







HLA	 proteins	 that	 interact	 with	 different	 NK	 cell	 inhibitory	 receptors	 (Killer-cell	
Immunoglobulin-like	Receptors,	KIR)	 such	as	HLA-C,	 can	 initiate	GVH	NK	cell	mediated	
alloreactions.	Post	transplantation,	NK	cells	will	be	generated	with	the	KIR	repertoire	of	
the	donor.	Included	within	this	NK	cell	population	will	exist	alloreactive	NK	cells	defined	
by	 their	 killing	 ability	 not	 being	 inhibited	 by	 the	HLA	proteins	 expressed	 by	 host	 cells	
including	 dendritic	 cells,	 T-cells	 and	 leukaemic	 cells	 resulting	 in	 a	 reduction	 in	 GVHD;	
prevention	of	graft	rejection	and	destruction	of	residual	leukaemic	cells	respectively.		







As	 with	 all	 related	 donor	 transplants	 identification	 of	 haplotypes	 within	 the	 family	
and/or	high	resolution	typing	of	the	potential	haplotype	matched	donor	is	required.	All	
haplo-identical	donors	will	be	at	least	a	5/10	match	to	the	patient.	Additional	matching	
on	 the	 mismatched	 haplotype	 may	 be	 observed,	 however	 a	 beneficial	 impact	 of	
additional	 matching	 alleles	 was	 not	 demonstrated	 in	 a	 retrospective	 study	 of	 185	
recipients	 of	 nonmyeloablative	 HLA-haploidentical	 transplants	 for	 haematological	
malignancies	 (Kasamon	 et	 al.,	 2010).	 Thus,	 when	 multiple	 haplo-identical	 donors	 are	








In	 a	 study	 of	 118	 patients	 receiving	 haploidentical	 transplants,	 an	 increase	 in	 5-year	
event	free	survival	(50.6%	±7.6%	versus	11.1%	±4.2%;	p<0.001)	due	to	reduced	relapse	
and	 reduced	 transplantation	 related	mortality	was	observed	when	 the	donor	was	 the	
mother,	 compared	 to	 the	 donor	 being	 the	 father	 (Stern	 et	 al.,	 2008).	 This	 reduced	
relapse	 rate	 in	 recipients	of	maternal	HPC	 is	 independent	of	NK	 cell	 alloreactions	and	
supports	an	earlier	study	(Kolb	et	al.,	2005).	 In	contrast	multi-variate	analyses	of	1210	
haploidentical	transplants	in	China	has	shown	that	transplants	where	the	mother	is	the	
donor,	 have	 increased	 NRM,	 aGVHD	 and	 decreased	 survival	 compared	 to	 transplants	
where	the	father	is	the	donor.	In	this	study	a	sibling	donor	with	NIMA	mismatches	was	
concluded	 to	 be	 the	 optimum	 donor	 (Wang	 et	 al.,	 2014).	 Thus	 there	 is	 currently	
insufficient	 evidence	 in	 the	 literature	 to	 support	 the	 use	 of	 particular	 haplo-identical	
donors	 from	within	 the	 family	and	optimum	donor	 selection	 should	 take	 into	account	
non-HLA	factors.		
Related	cord	blood	donor	















1. HLA	 high	 resolution	 typing	 should	 be	 performed	 on	 potential	 matching;	


















decision	 to	 initiate	 an	 unrelated	 donor	 search	must	 be	made	 in	 conjunction	with	 the	








Within	 the	UK,	 there	 is	 an	aligned	unrelated	donor	 registry,	operated	by	 the	Anthony	
Nolan,	 providing	 search	 reports	 with	 details	 of	 donors	 from	 the	 Anthony	 Nolan;	 the	
British	 Bone	 Marrow	 Register	 (BBMR);	 the	 Welsh	 Bone	 Marrow	 Donor	 Register	
(WBMDR)	and	Delete	Blood	Cancer	UK.	Search	requests	are	sent	to	the	Anthony	Nolan	
and	a	search	report	of	UK	donors,	together	with	a	summary	report	of	the	results	from	a	
















comparing	 donor-patient	 pairs	 irrespective	 of	 whether	 their	 HLA	 typing	 derives	 from	
serologic	or	DNA	based	methods.	These	comparisons	are	based	around	the	assignment	
of	a	search	determinant	to	each	HLA	allele	or	National	Marrow	Donor	Program	(NMDP)	















all	 regions	 (exons	 and	 introns)	 underlying	 the	 current	 definition	 of	 the	 allele	
name,	e.g.	A*02:01:01:01	vs.	A*02:01:01:01.	
• Amino	Acid	 Sequence	Match	 -	a1	and	a2	have	 identical	amino	acid	sequences	
but	 differ	 within	 their	 nucleotide	 sequences,	 e.g.	 A*01:01:02	 vs.	 A*01:01:03,	
B*40:06:01:01	vs.	B*40:06:01:02.	












Currently	 the	 algorithm	 used	 in	 the	 UK	 by	 the	 Anthony	 Nolan	 shortlists	 potential	
matching	 donors	when	HLA-A,	 -B	 and	 -DRB1	 potentially	match	 but	 does	 not	 consider	
matching	beyond	the	first	 field	of	the	HLA	type	for	HLA-C	and	-DQB1,	when	typing	for	
these	 loci	 are	 available.	 The	 search	 requester	must	 check	 the	 true	 level	 of	 matching	
which	involves	decoding	NMDP	HLA	typing	codes	to	determine	whether	the	shortlisted	
potential	matching	donors	have	mismatches	at	HLA-C	and	-DQB1.		














The	 number	 of	 HLA-A,	 -B	 and	 -DRB1	 low	 resolution	 matched	 donors	 available	 for	 a	






that	 are	 less	well	 represented	on	 the	unrelated	donor	 registries,	 is	 significantly	 lower	
(Heemskerk	et	al.,	2005;	Schmidt	et	al.,	2009	and	Gragert	et	al.,	2014).	Hence,	patients	
are	 less	 likely	 to	 find	a	matched	donor	 from	an	ethnic	group	differing	 from	 their	own	
and	 patients	 with	 parents	 coming	 from	 differing	 ethnic	 groups	 (mixed	 race)	 are	 at	
increased	risk	of	not	finding	any	match.	
	


















in	 linkage	 disequilibrium	 with	 alleles	 of	 the	 neighbouring	 locus,	 such	 as	















Multiple	 studies	 have	 reported	 optimum	 transplant	 outcome	 is	 achieved	 when	 the	





for	malignant	 disease	 (Lee	 et	 al.,	 2007),	 showed	 that	 individual	mismatches	 for	 HLA-
DQB1	had	no	impact	on	survival.	However	if	the	DQB1	mismatch	was	associated	with	an	
additional	mismatch	e.g.	7/8	or	6/8	HLA-A,	 -B,	 -C,	 -DRB1	mismatch,	then	there	was	an	
association	with	 poorer	 survival	 albeit	 not	 statistically	 significant.	 Although	HLA-DQB1	
mismatching	did	not	reach	significance	in	relation	to	survival,	in	a	recent	German	study	













There	 is	 no	 consensus	 regarding	 which	 of	 the	 HLA-A,	 -B,	 -C,	 -DRB1	 loci	 are	 more	
detrimental	 to	mismatch.	 HLA-A	 and	 -DRB1	mismatching	were	 reported	 as	 being	 less	
well	 tolerated	 compared	 to	 HLA-B	 and	 -C	 mismatches	 in	 a	 NMDP	 study	 with	 all	
mismatches	reducing	overall	survival	at	1	year	by	9-10%	(Lee	et	al.,	2007).	 In	contrast,	
the	 Japanese	 registry	 reported	 transplants	with	 HLA-A	 and	 -B	mismatches	 had	worse	
survival	than	HLA-C	and	-DRB1	mismatches	(Morishima	et	al.,	2002).	HLA-B	mismatches	
were	 associated	 with	 a	 higher	 risk	 of	 aGVHD	 II-IV	 in	 an	 Italian	 study	 of	 805	 patients	
transplanted	for	haematological	malignancies	(Crocchiolo	et	al.,	2009a)	whereas	HLA-C	
antigen	mismatches	were	associated	with:	lower	leukaemia	free	survival;	increased	risk	
for	 mortality	 and	 grade	 III-IV	 GvHD	 in	 an	 NMDP/	 Centre	 for	 International	 Blood	 and	
Marrow	 Transplant	 Research	 	 (CIBMTR)	 study	 of	 1933	 patients	 transplanted	 with	
haematological	malignancies	(Woolfrey	et	al.,	2011).	The	variability	in	the	outcomes	of	





malignancies	 in	 Germany	 has	 been	 performed	 (Fürst	 et	 al.,	 2013).	 All	 patients	 and	
donors	were	HLA	typed	to	high	resolution.	The	 impact	of	mismatches,	defined	at	both	
high	 (allele)	 and	 low	 (antigen)	 resolution,	 on	 overall	 survival;	 disease	 free	 survival;	













disease	 free	 survival	 (significant	 for	 HLA-C)	 and	 an	 increase	 in	 transplant	 related	
mortality	 (significant	 for	 HLA-A,	 -B,	 -C	 and	 –DRB1).	 Of	 all	 associations	 observed,	 the	
most	 significant	 were	 with	 HLA-C	 antigen	 mismatches,	 affecting	 overall	 survival	 and	
disease	free	survival,	with	HLA-B	allele	mismatching	being	the	most	significant	affecting	








study	 of	 1975	 HLA-C	 only	 mismatched	 (matched	 HLA-A,	 -B,	 and	 -DRB1)	 transplants	
(Petersdorf	et	al.,	2014).	The	 level	of	expression	of	 the	mismatched	HLA-C	alleles	was	
assessed	using	median	fluorescence	 intensity	(MFI)	data	procured	from	previous	study	
of	 healthy	 and	Human	 Immunodeficiency	Virus	 (HIV)	 infected	 individuals	 (Apps	et	 al.,	
2013).	 Patients	 with	 low	 expressing	 mismatched	 HLA-C	 alleles	 and	 antigens	 were	
associated	with	a	decreased	risk	of:	aGVHD	III-IV;	NRM	and	overall	mortality	but	with	no	
impact	 on	 relapse	 compared	 to	 the	 non-shared	 HLA-C	 being	 a	 low	 expressor.	 The	
presence	 of	 a	 high	 expressing	 mismatched	 (non-shared)	 HLA-C	 allele/antigen	 in	 the	
donor	was	also	associated	with	an	increase	in	NRM	and	mortality,	but	with	no	effect	on	
aGvHD	 or	 relapse.	 The	 allele	mismatches	 were	 predominantly	 C*07	 and	 C*03,	 which	
have	been	shown	to	have	low	levels	of	expression,	and	these	mismatches	may	account	
for	 the	 previously	 reported	 permissive	 HLA-C	 mismatches.	 Mismatching	 for	 lower	
expressing	 HLA-C	 alleles	 of	 the	 patient,	 compared	 to	 higher	 expressing	 HLA-C	 alleles	
may	 lower	 the	 GVH	 immune	 response	 supporting	 selection	 of	 mismatches	 for	 lower	
expressed	allotype	over	mismatches	for	high	expressed	alleles,	and	avoidance	of	HLA-C	












may	 involve	one	 versus	 10	 versus	 20	 amino	acid	mismatches	 e.g.	A*01:01	 v	A*02:01;	
A*01:01	v	A*03:01;	A*01:01	v	A*23:01	and	not	all	mismatches	at	a	given	loci	will	have	
equal	effects	on	GVL	and	GVH	immune	responses	post	transplant.	It	has	been	calculated	
that	 a	 database	 of	 11,000	 to	 1.3	 million	 transplants	 would	 be	 required	 to	 provide	






(TRM),	 relapse	 and	 overall	 survival)	 of	 amino	 acid	 substitution	 at	 peptide	 binding	
positions	9,	99,	116	and	156,	and	KIR	binding	position	at	amino	acid	77	was	studied	in	a	








had	 an	 increased	 risk	 of	 aGVHD	 compared	 to	 residue	 116	 matched	 patients	 and	 a	
slightly	higher	risk	of	overall	mortality.	These	 findings	were	not	statistically	significant.	
However	 the	 incidence	 of	 NRM	 was	 found	 to	 increased	 in	 patients	 that	 were	
mismatched	for	residue	116	as	the	expression	of	the	HLA-C	mismatch	also	increased	(HR,	







at	 KIR	 interacting	 residues	 77	 and	 80,	 had	 HLA-C	mismatches	 with	 higher	 expression	
compared	 to	 patients	 with	 matching	 residues	 77	 and	 80.	 No	 statistical	 significant	
associations	with	aGVHD,	overall	mortality	or	NRM	were	identified,	although	similar	to	
mismatching	 at	 residue	 116,	 the	 risk	 of	 NRM	 increased	 as	 the	 HLA-C	 mismatch	
expression	 levels	 increased	 for	 the	 patients	 receiving	 residue	 77	 and	 80	mismatched	
transplants	(HR,	1.38;	95%	CI,	1.14-1.67;	P	=	0.0009).	This	was	not	observed	for	patients	
receiving	residue	77	and	80	matched	transplants	(HR,	1.01;	95%	CI,	0.82-1.24;	P	=	0.91).	




the	 mismatched	 amino	 acid	 residues	 and	 avoidance	 of	 the	 described	 non-permissive	






DRB1,	 -DQB1	haplotypes,	does	not	necessarily	 implicate	matching	 for	HLA-DPB1	and	 -
DPA1	alleles.	 It	 is	 reported	 that	within	 families	up	 to	5%	of	otherwise	10/10	matched	
siblings	will	 also	be	HLA-DPB1	mismatched	attributed	 to	 recombination	between	HLA-
DQ	and	-DP	genes	(Büchler	et	al.,	2002).	HLA-DP	specific	T-cells	have	been	detected	and	
associated	with	both	GVL	(Rutten	et	al.,	2008,	Rutten	et	al.,	2013)	and	GVHD	(Stevanovic	




has	 been	 studied	 in	 both	 single	 centre	 and	 multi-centre	 studies.	 In	 an	 analysis	 of	 a	
heterogenous	 international	 cohort	 of	 transplant	 recipients,	 allelic	 DPB1	 mismatches	
were	 shown	 to	 offer	 a	 GVL	 advantage	 via	 a	 reduction	 in	 relapse,	 but	 this	 was	 also	










In	 a	 UK	 multicentre	 study,	 the	 impact	 of	 DPB1	 allele	 matching	 was	 associated	 with	
better	overall	survival	in	patients	transplanted	with	early	leukaemia	but	not	in	patients	
transplanted	with	late	stage	disease	(Shaw	et	al.,	2010),	supporting	other	studies	where	
the	effect	of	HLA	matching	 is	not	as	strong	 in	patients	 transplanted	at	 late	stage.	This	













2009b).	 The	 effect	 of	 dividing	 DPB1	mismatches	 into	 these	 two	 groups	 has	 provided	
evidence	of	DPB1	mismatching	impacting	on	survival.	In	a	study	of	621	unrelated	donor	
HPC	transplants,	recipients	with	permissive	DPB1	mismatches	had	a	significantly	higher	
2-year	 survival	 than	 those	 with	 non-permissive	 DPB1	 mismatches	 (55%	 versus	 39%,	











2012).	 Of	 the	 patients	 receiving	 a	 10/10	matched	 transplant	 (HLA-A,	 -B,	 -C,	 -DRB1,	 -
DQB1),	 HLA-DPB1	 non-permissive	 mismatches	 were	 associated	 with	 a	 significant	
increased	risk	of	overall	mortality	(HR	1.15,	95%	CI	1.05-1.25;	P=0.002);	NRM	(HR	1.28,	
1.14-1.42;	P<0.0001)	and	 in	 this	 study	an	association	was	observed	with	severe	GVHD	
(OR	1.31,	95%	CI	1.11-1.54;	P=0.001)	but	not	relapse	(HR	0.89,	95%	CI	0.77-1.02;	P=0.10)	
compared	 to	permissive	mismatches.	Although	differences	 in	outcome	were	observed	
between	 the	 DPB1	 matched	 and	 DPB1	 permissive	 mismatched	 patients,	 this	 did	 not	
affect	overall	mortality.	
	
A	 CIBMTR	 study	 of	 a	 patient	 cohort	 considered	 more	 contemporaneous	 based	 on,	
patient	disease,	transplant	conditioning	protocol	and	HPC	source	(peripheral	blood	stem	
cell,	 PBSC	 versus	 bone	marrow),	 has	 addressed	 the	 impact	 of	 DPB1	matching	 versus	
permissible	and	non-permissive	mismatches	(Pidala	et	al.,	2014).	An	increase	in	aGVHD	
grades	 II	 to	 IV	 and	 III	 to	 IV	 and	 a	 decrease	 risk	 of	 relapse	 was	 observed	 in	 patients	
receiving	 DPB1	 mismatched	 donors.	 Dividing	 the	 DPB1	 mismatched	 donors	 into	
permissive	 and	 non-permissive	mismatches	 identified	 the	 non-permissive	mismatches	
as	having	an	increase	in	transplant	related	mortality	and	an	increase	in	overall	mortality	









Although	 there	 are	 variations	 in	 the	 clinical	 outcomes	 for	 HLA-DPB1	 allele	 and	 non-
permissive	mismatched	 transplants,	 overall,	matching	 for	HLA-DPB1	 and	 avoidance	 of	
non-permissive	 mismatches	 is	 associated	 with	 better	 overall	 survival.	 	 Therefore,	






evaluation	 of	 the	 patient’s	 transplant	 related	 risks.	 An	 online	 tool	 is	 available	 for	




Further	 analysis	 of	 the	 NMDP	 dataset	 of	 3853	 unrelated	 donor	 transplants	 has	
demonstrated	that	whilst	not	significant	 in	 isolation,	mismatching	for	DRB3/4/5,	DQB1	
and	DPB1	(defined	as	“lesser	expressed	HLA	loci”,	LEL)	increased	the	risk	associated	with	
the	 presence	 of	 a	mismatch	 at	 HLA-A,	 -B,	 -C	 or	 -DRB1	 (Fernandez-Viña	 et	 al.,	 2013).	
Transplants	matched	for	7/8	HLA-A,	-B,	-C,	-DRB1	with	three	or	more	LEL	mismatches	in	
the	GvH	direction	had	a	higher	 risk	of	mortality	 and	 transplant	 related	mortality	 than	
7/8	 transplants	with	 0	 or	 1	 LEL	mismatches.	 Thus	HLA	 typing	donors	 and	patients	 for	




Donor	 and	 patient	 HLA	 mismatches	 may	 be	 bidirectional	 i.e.	 GVH	 and	 HVG	 or	
unidirectional	e.g.	GVH	(when	the	donor	 is	homozygous	for	a	particular	 locus)	or	HVG,	




and	patients	 receiving	 a	 7/8	bidirectional	mismatch	had	 significantly	worse	 transplant	
related	 mortality;	 overall	 survival	 and	 disease-free	 survival	 compared	 to	 patients	
receiving	 a	 8/8	matched	 transplant.	 This	worse	 transplant	outcome	 (compared	 to	8/8	




observed	 reduction	 in	 probability	 of	 acute	 GVHD	 observed	 in	 this	 group,	 which	 was	
significantly	 less	 than	 the	 7/8	 bidirectional	 mm	 and	 7/8	 GVH	mm	 (P=0.003)	 and	 not	











transplants	 mismatched	 in	 the	 HVG	 direction	 were	 associated	 with	 lower	 neutrophil	
engraftment	and	secondary	graft	 failure.	However	 the	demographics	of	 the	 transplant	













transplant	 policies.	 If	 the	 patient	 is	 to	 be	 entered	 onto	 a	 clinical	 trial	 that	 requires	 a	
10/10	matching	donor,	then	the	H&I	specialist	must	be	informed	to	avoid	wasting	time	
searching	for	mismatched	donors	if	there	are	no	fully	matched	donors	available	and	the	














4. Alternative	 progenitor	 cell	 donors	 (cord	 blood	 or	 haplo-identical)	 should	 be	
considered	early	in	the	donor	search	when	a	patient	is	unlikely	to	have	an	HLA	
matched	unrelated	donor	(Grade	1A).	
5. HLA-DRB3,	 -DRB4,	 -DRB5	 typing	 should	 be	 performed	 and,	when	 a	 choice	 of	
otherwise	 equally	 matched	 and	 appropriate	 (e.g.	 CMV	 status)	 donors	 is	
available,	mismatches	for	these	should	be	minimized	(Grade	2A).																																																																																			
6. For	 unrelated	 donor	 selection,	 HLA-DPB1	 typing	 should	 be	 performed	 and	
when	a	choice	of	otherwise	equally	matched	and	appropriate	(e.g.	CMV	status)	
donors	 is	 available,	 non-permissive	mismatches	 should	 be	minimised	 (Grade	
2C).	
7. For	mismatched	 related	 and	 unrelated	 donor	 selection,	HVG	mismatches	 are	
favoured	over	bi-directional	and	GVH	mismatches	(Grade	2C).	








comparing	 patients	 receiving	 HLA-identical	 cord	 blood	 transplants	 with	 patients	
receiving	 HLA-identical	 sibling	 donor	 transplants.	 This	 study	 highlighted	 delayed	
granulocyte	 and	 platelet	 engraftment	 in	 UCB	 transplant	 recipients	 but	 also	
demonstrated	a	reduction	in	both	acute	and	chronic	GVHD	(Rocha	et	al.,	2000).		
	
Similarly	 a	 comparison	 of	 unrelated	 HLA	 mismatched	 UCB	 transplants	 with	 matched	
unrelated	 adult	 donors	 transplants	 demonstrated	 recipients	 of	 the	 UCB	 transplants	








poorer	 results	 obtained	 with	 adult	 recipients	 (Laughlin	 et	 al.,	 2001).	 However	 the	
selection	of	UCBs	with	higher	cell	doses	and	the	success	with	 infusion	of	 two	UCBs	 to	











observed	 in	recipients	of	0	mismatched	units	 (HLA-A,	 -B	 low/intermediate;	 -DRB1	high	
resolution)	 regardless	 of	 cell	 dose.	 For	 transplants	 performed	 with	 HLA	 mismatches,	








that	 independent	 to	 HLA	 matching,	 UCB	 TNC	 dose	 was	 the	 only	 other	 donor	 factor	
associated	with	NRM.	Transplants	performed	with	single	UCB	units	with	<3x107TNC/kg	
had	 NRM	 rates	 that	 were	 15-20%	 higher	 than	 transplants	 performed	 with	 UCB	 units	
with	a	higher	TNC.	
	




















The	 role	 of	 allele	 level	HLA	matching	 between	UCB	 and	 patient	was	 investigated	 in	 a	
cohort	 of	 1568	 recipients	 of	 single	 cord	 blood	 transplants	 for	 haematological	
malignancies	(Eapen	et	al.,	2014).		The	patients	were	predominantly	paediatric.	Analysis	





alleles	 having	 reduced	 risk	 compared	 to	 transplants	 performed	 with	 3,	 4	 or	 5	 allele	
mismatches.	The	results	suggest	that	isolated	mismatches	at	HLA-A,	-C	or	-DRB1	but	not	
HLA-B	are	associated	with	a	threefold	increase	in	NRM	risk	suggesting	an	isolated	HLA-B	
mismatch	 may	 be	 better	 tolerated,	 although	 this	 finding	 has	 to	 be	 considered	 with	
caution	 as	 there	 were	 only	 31	 donor/patient	 pairs	 with	 isolated	 HLA-B	 mismatches	














UCB	units	available	with	TNC	≥3x107/kg,	 it	 is	not	necessary	to	select	 the	UCB	with	the	





The	 impact	 of	 allele	 level	 mismatching	 on	 outcome	 in	 double	 cord	 transplants	 has	
recently	 been	 described	 in	 a	 single	 centre	 cohort	 of	 133	 patients	 transplanted	 for	






or	 HVG	 (rejection)	 mismatches.	 Engraftment	 was	 faster	 in	 patients	 with	 GVH	
unidirectional	mismatches	 compared	 to	patients	with	 single	bi-directional	mismatches	
HR=1.6,	 P=0.003).	 Other	 benefits	 to	 unidirectional	 mismatches	 included	 lower	 TRM,	
















significant	 association	 with	 overall	 mortality	 for	 transplants	 performed	 with	
unidirectional	 mismatches	 in	 either	 GVH	 or	 HVG	 direction	 (Kanda	 et	 al.,	 2013).	 GVH	
mismatches	were	 associated	with	 a	 lower	 incidence	 of	 NRM	 for	 paediatric	 recipients	
only	which	were	also	associated	with	a	higher	incidence	of	relapse.	
	
The	 HLA	 data	 included	 in	 these	 three	 studies	 was	 not	 at	 high	 resolution	 therefore	
additional	mismatches	not	accounted	for	 in	the	analysis	are	likely.	HLA-C,	-DQ	and	-DP	
matching	was	 not	 considered.	 The	 role	 of	HLA	 alloantibodies	was	 not	 addressed.	 The	
impact	of	NIMA	matching	was	included	in	the	study	of	Stevens	et	al.,	(2011),	but	not	in	
the	others.	These	studies	are	also	complicated	as	multiple	mismatches	are	present	and	











A	 study	 of	 128	 double	UCB	 transplants	 performed	 in	 patients	with	malignant	 disease	
identified	 the	 cord	 blood	 bank	 precryopreservation	 CD34+	 cell	 dose	 of	 the	 dominant	
UCB	unit	as	the	only	independent	predictor	of	neutrophil	engraftment	(HR,	1.95;	95%CI:	
1.30-2.90;	 P=<0.001)	 (Purtill	 et	 al.,	 2014).	 The	 precryopreservation	 CD34+	 cell	 dose	
correlated	 with	 the	 transplant	 centres	 post	 thaw	 CD34+	 cell	 count,	 with	 better	
correlation	for:	i)	UCB	units	from	cord	blood	banks	that	were	FACT-Netcord		accredited	







Cryopreserved	 UCB	 units	 with	 volumes	 <24.5	 and	 >26.0	ml	 and	 UCB	 units	 from	 non-









A	 search	 for	 an	 UCB	 unit	 can	 be	 undertaken	 simultaneously	 with	 an	 adult	 unrelated	
donor	search.	This	is	essential	if	the	patient	has	a	rare	HLA	type	or	if	the	patient	requires	
a	speedy	transplant.	Within	the	UK	a	joint	Anthony	Nolan	and	BBMR	cord	blood	search	
report	 is	 produced	 when	 requested.	 International	 cord	 blood	 units	 are	 listed	 on	 the	





































Until	 recently	 the	 impact	 of	 HLA	 antibodies	 on	 HPC	 engraftment	 has	 been	 unclear.	
Opinion	was	 formed	 from	 contradictory	 case	 study	 reports	 in	 the	 literature	with	 few	
cases	 available	 for	 analysis	 because	of	 the	matching	 criteria	 inherent	 in	HLA	matched	
related	 and	unrelated	donor	 transplants.	 The	use	 of	HLA	mismatched	 cord	 blood	 and	
related	haploidentical	donors	has	 led	 to	more	 transplants	being	performed	where	 the	





















A	 further	American	study	of	73	double	cord	blood	 transplants	 revealed	 that	18	of	 the	
patients	 had	 donor	 specific	 antibodies	 (Cutler	 et	 al.,	 2011).	 Nine	 patients	 had	 DSA	















Similar	 results	 emerged	 from	 a	 Eurocord	 registry	 analysis	 of	 UCB	 transplants	 (60%	
double	 cord)	 performed	 after	 RIC	 regimen	 (Ruggeri	 et	 al.,	 2013).	 Of	 294	 patients,	 62	
patients	(21%)	had	detectable	HLA	alloantibodies;	14	with	DSA	(7	double	cord	recipients	












These	 studies	 indicate	 that	 in	 HLA	 mismatched	 HPC	 transplants,	 HLA-DSA	 in	 the	
recipient	should	be	considered	as	a	significant	risk	factor	for	non-engraftment	and	that	





search	 and	 should	 be	 repeated	 at	 the	 time	 of	 donor	work-up	 request	 if	 an	 HLA	
mismatched	donor	is	selected	(Grade	1A)	
2. The	 clinical	 team	must	 be	made	 aware	 of	 any	 HLA	 alloantibody	 incompatibility	
detected	in	the	recipient	(Grade	1A)		









CMV	 infection	 can	 cause	 significant	 complications	 post	 transplantation.	 CMV	 disease	
affects	 different	 organs	 including,	 lung	 (pneumonia);	 liver	 (hepatitis);	 gut	
(gastroenteritis);	 eye	 (retinitis)	 and	 the	 brain	 (encephalitis).	 Even	 with	 recent	
improvements	 in	 anti-viral	 prophylactic	 therapies,	 CMV	 seropositivity	 remains	
associated	 with	 an	 adverse	 prognosis	 and	 is	 still	 a	 major	 cause	 of	 morbidity	 and	
mortality	 in	 allogeneic	 SCT	 (reviewed	 in	 Ljungman	 2014a).	 CMV	 positivity	 can	 be	








(Schmidt-Hieber	 et	 al.,	 2013)	 reported	 that	 donor	 or	 recipient	 CMV	 seropositivity	
(versus	 donor	 and	 recipient	 CMV	 seronegativity)	 was	 associated	 with	 a	 significant	
decrease	in	leukaemia	free	survival	and	overall	survival	with	an	increase	in	NRM	and	a	
small	 increase	 in	 relapse	 incidence.	The	negative	 impact	on	disease	 free	survival	 (DFS)	
and	 OS	 held	 up	 in	 multivariate	 analyses.	 OS	 was	 reduced	 in	 ALL	 (46%	 for	 CMV	
seropositive	donor	and/or	patient	versus	55%	for	CMV	seronegative	donor	and	patient)	














The	 impact	 of	multiple	 donor	 factors	 including	 CMV	on	 survival	was	 investigated	 in	 a	
multi-centre	 study	 of	 1271	 UK	 patients	 transplanted	 with	 an	 unrelated	 donor	 for	
malignant	disease	(Shaw	et	al.,	2014).		Patients	who	were	CMV	seropositive	at	the	time	
of	transplant	had	a	reduced	median	survival	(1.7	years)	compared	to	CMV	seronegative	










seropositive	 patients	 with	 a	 10/10	 HLA	 matched	 donor	 at	 1.8	 years	 with	 a	 CMV	
seronegative	donor	and	2.4	years	with	a	seropositive	donor	(p=0.23).	When	the	donor	
was	 a	 9/10	 HLA	match,	 the	 median	 survival	 was	 0.7	 years	 with	 a	 CMV	 seronegative	
donor	compared	to	2.2	years	with	a	CMV	seropositive	donor	(p=0.004).	The	difference	




CMV	 seropositive	 patients	 receiving	 transplants	 from	 CMV	 seropositive	 donors	 have	







Analysis	 of	 29,349	 CMV	 seropositive	 transplant	 recipients	 identified	 within	 the	 EBMT	
registry	 found	 no	 effect	 of	 donor	 CMV	 status	 on	 outcome	 for	 transplants	 performed	
with	 a	matched	 or	mismatched	 family	 donor	 (Ljungman	 et	 al.,	 2014b).	 An	 effect	was	
observed	 for	 CMV	 seropositive	 patients	 receiving	 transplants	 from	 unrelated	 donors	
with	lower	relapse	mortality	observed	albeit	at	borderline	significance	(HR	0.94;	P=.05)	
when	 a	 CMV	 seropositive	 donor	 was	 used.	 For	 patients	 receiving	 myeloablative	
conditioning	 better	 overall	 survival;	 lower	 NRM	 and	 improved	 relapse-free	 survival	
outcomes	were	observed	when	the	donors	were	CMV	seropositive.	Similar	effects	were	
not	observed	for	patients	transplanted	with	RIC.		The	retention	of	host	CMV	specific	T-
cell	 function	 in	 patients	 receiving	 RIC	 is	 an	 explanation	 for	 the	 lack	 of	 an	 association	
observed	(Ljungman	et	al.,	2014b).			
	
The	British	Committee	 for	Standards	 in	Haematology,	 the	British	Society	of	Blood	and	









ABO	 incompatibility	 (ABOi)	 between	 patient	 and	 donor	 is	 a	 common	 feature	 of	 HPC	
transplantation.	 The	 ABOi	 can	 be	major,	minor	 or	 bidirectional	 (Table	 1).	Major	 ABOi	
transplants,	 in	 particular	 for	 blood	 group	 O	 patients,	 can	 cause	 delayed	 red	 cell	
engraftment,	 and	 infrequently	 pure	 red	 cell	 aplasia	 (PRCA).	 Reduced-toxicity	 regimes	
such	 as	 low	 intensity	 conditioning	 and	 graft	 versus	 host	 prophylactics	 are	 associated	
with	extended	host	isohaemaglutinin	production	and	PRCA	(Bolan	et	al.,	2001).	
	
Major	 and	 minor	 ABO	 incompatibilities	 do	 not	 have	 a	 significant	 effect	 on	 overall	
survival	and	incidence	of	GVHD	(reviewed	in	Booth	et	al.,	2013)	and	do	not	constitute	a	
major	 contraindication	 to	 donor	 selection.	 	 However	 there	 are	 several	 single-centre	
studies	that	indicate	ABOi	having	an	impact	on	clinical	outcome.	
	
Recipients	 of	major	 and	minor	 ABOi	 RIC	 transplants	 are	 dependent	 on	 red	 blood	 cell	
transfusions	for	longer	compared	to	ABO	compatible	RIC	transplants	(Watz	et	al.,	2014).	
Patients	receiving	major	ABOi	RIC	transplants	who	then	developed	persistent	recipient	





identified	 27%	 of	 patients	 received	 major	 ABOi	 transplants	 and	 7.5%	 of	 these	 major	
ABOi	transplanted	patients	developed	PRCA	(Aung	et	al.,	2013).	Chimerism	studies	for	T-
cell	 and	myeloid	cell	 lineage	and	 time	 to	engraftment	 for	neutrophil	 and	platelets	did	
not	differ	significantly	for	the	major	ABOi	patients	that	did,	and	did	not	develop	PRCA.	
All	 patients	 with	 PRCA	 required	 red	 cell	 transfusion	 support	 for	 several	 months	 and	














Using	 a	male	donor	has	been	 reported	 in	 some	 studies	 as	 having	 a	 positive	 effect	 on	
long	 term	 survival	 regardless	 of	 the	 sex	 of	 the	 recipient	 (Gustafsson	 et	 al.,	 2004	 and	
Pond	et	al.,	2006)	but	not	 in	others	 (Lee	et	al.,	2007).	Regardless,	donor	sex	selection	
priority	 is	usually	given	to	male	donors	due	of	 their	usually	 larger	size	associated	with	
higher	HPC	 counts	 obtained	 and	 also	 because	 of	 the	 increase	 in	GVHD	 that	 has	 been	
reported	with	female	multiparous	donors	(Kollman	et	al.,	2001).	A	recent	German	study	
of	2,646	transplants	performed	in	patients	with	haematological	malignancies	found	that	
transplants	 performed	 with	 international	 donors	 had	 a	 worse	 outcome	 compared	 to	









An	 investigation	 into	 the	 impact	 of	 cord	 blood	 donor	 sex	 compatibility	 has	
demonstrated	 no	 impact	 on	 survival	 in	 adults	 with	 haematological	 malignancies	
receiving	a	myeloablative	single	unit	cord	blood	transplant.	However,	a	higher	incidence	
of	chronic	GVHD	(HR	2.97,	P=0.02)	was	observed	in	male	recipients	of	female	cord	blood	
donors	 and	 a	 lower	 incidence	 of	 platelet	 engraftment	 (HR	 0.56,	 P=0.02)	 in	 female	








In	 a	 2001	NMDP	 study	of	 6,978	unrelated	donor	 transplants	performed	 from	1987	 to	
1999	 recipients	 receiving	 transplants	 from	younger	 aged	donors	were	associated	with	
lower	 levels	 of	 aGvHD	 III-IV	 (30%	 18-30	 years;	 34%	 31-45	 years	 and	 34%	 >45	 years,	
p=0.005)	and	cGvHD	(44%	18-30	years;	48%	31-45	years	and	49%	>45	years,	p=0.02)	and	
improved	5	year	overall	survival	(33%	18-30	years;	29%	31-45	years	and	25%	>45	years,	
p=0.0002)	 (Kollman	 et	 al.,	 2001).	 The	 transplants	 included	 in	 this	 study	 were	 not	 all	
matched	 for	 high	 resolution	 HLA	 typing	 and	 included	 both	 HLA	 matched	 and	




A	 recent	 study	 of	 donor	 age	 in	 both	matched	 sibling	 transplants	 and	 high	 resolution	
matched	 unrelated	 transplants	 found	 no	 significant	 difference	 in	 overall	 survival	 in	
recipients	 of	 transplants	 from	matched	 unrelated	 donors	 in	 three	 age	 groups:	 	 19-29	
years	(n=254)	vs.	30-39	years	(n=306)	vs.	40-49	years	(n=194);	p=0.5	(Alousi	et	al.,		2013).	
This	 study	 only	 included	 patients	 over	 the	 age	 of	 50	 which	 may	 have	 impacted	 the	
results	obtained.	
	
A	 CIBMTR	 study	 (GS08-01)	 of	 6,349	 transplants	 examining	 the	 effect	 of	 donor	
characteristics	 on	 GVHD	 and	 survival	 following	 unrelated	 donor	 HPC	 transplantation	
identified:	 donor	 age;	 high	 resolution	 HLA	 matching	 and	 blood	 group	 matching	
associated	with	overall	survival.	Specifically	patients	transplanted	from	older	donors	had	






reactions	 are	 mediated	 by	 receptors	 on	 the	 NK	 cells	 and	 ligands	 on	 the	 target	 cells	






GVH	 NK	 cell	 mediated	 alloreactions.	 Post	 transplantation,	 NK	 cells	 will	 be	 generated	
with	 the	KIR	 repertoire	of	 the	donor.	 Included	within	 this	NK	cell	population	will	exist	
alloreactive	 NK	 cells	 defined	 by	 their	 killing	 ability	 not	 being	 inhibited	 by	 any	
mismatched	HLA	proteins	 expressed	 by	 host	 cells	 including	 dendritic	 cells,	 T-cells	 and	




Ruggeri	 et	 al.	 (2002)	 who	 demonstrated	 improved	 survival	 attributed	 to	 decreased	
relapse,	GVHD	and	 rejection	 in	AML	patients	 receiving	KIR	 ligand	 (HLA-C)	mismatched	
transplants.	The	mechanism	for	this	effect	was	attributed	to	the	donor	possessing	allo-
reactive	 NK	 cells	 that	 were	 not	 inhibited	 by	 the	 patient’s	 mismatched	 HLA-C	 allele.	
However	the	results	observed	in	this	study	have	not	been	extensively	reproduced	with	
some	 studies	 reporting	 worse	 overall	 survival	 (Leung	 2011).	 This	 is	 attributed	 to	





KIR	genes	are	 located	on	chromosome	19,	and	as	such	are	 inherited	 independently	of	





survival	 that	 was	 significantly	 higher	 that	 transplants	 performed	 with	 donors	 that	
possessed	 two	 KIR	 A	 haplotypes	 (31%	 v	 20%,	 p=0.007)	 (Cooley	 et	 al.,	 2009).	 Further	
studies	have	associated	the	presence	of	KIR	B	in	the	donor	with	relapse	protection	and	
improved	 survival	 for	 patients	 with	 AML	 but	 not	 ALL,	 with	 homozygosity	 for	 KIR	 B	







ALL	 demonstrated	 decreased	 rate	 of	 relapse	 for	 AML	 but	 not	 ALL	 patients	 when	 the	
donor	 possessed	 the	 KIR	 B	 haplotype	 gene	 KIR2DS1	 in	 association	 with	 the	 donor	
possessing	 one	 or	 two	HLA-C	 allotypes	with	 the	 C1	 epitope	 (not	 ligands	 for	KIR2DS1)	
compared	 to	 donors	 that	 were	 HLA-C	 homozygous	 for	 the	 C2	 epitope	 (ligands	 for	
KIR2DS1)	 or	 negative	 for	 KIR2DS1.	 Mismatching	 for	 HLA-C	 in	 the	 absence	 of	 donor	
KIR2DS1	did	not	impact	on	relapse.	Individuals	that	are	KIR2DS1	and	HLA-C	C2	epitope	
homozygotes	have	previously	been	shown	to	be	hyporesponsive	to	target	cells	due	to	a	
tolerogenic	 effect	 of	 the	 interaction	 between	 KIR2DS1	 and	 its	 self	 ligand	 (Sun	 et	 al.,	
2008	and	Tripathy	et	al.,	2008)	supporting	an	alloreactive	response	mediated	by	NK	cells	
expressing	 KIR2DS1	 and	 HLA-C	 with	 the	 C1	 epitope.	 The	 presence	 of	 HLA-C	 with	 C1	
epitope	 within	 the	 patient	 also	 associated	 with	 reduced	 relapse	 when	 the	 donor	
expressed	KIR2DS1.	This	was	not	observed	when	the	patient	was	homozygous	for	HLA-C	









Patients	 possessing	 one	 or	 two	 HLA-C	 allotypes	with	 the	 C1	 epitope	were	 associated	
with	 improved	LFS	attributed	to	a	reduction	 in	relapse	when	the	donor	possesses	2	or	
more	KIR	B	motifs,	but	not	when	the	donor	possessed	1	or	0	B	motifs.	This	effect	was	
most	 significant	 for	 the	 HLA-C	 mismatched	 transplants	 with	 enhanced	 LFS	 (RR	 0.57	
[0.40-0.79],	p=0.001)	and	reduced	relapse	(RR	0.54	[0.33-0.88],	p=0.013).	Comparison	of	
the	HLA-C	mismatches,	within	this	subset	of	transplants,	did	not	show	a	benefit	for	KIR	
ligand	 (C1	 and	 C2	 epitope)	 mismatching.	 This	 data	 supports	 a	 benefit	 of	 HLA-C	







for	 the	 Bw4	 and	 C2	 epitopes	 when	 present	 in	 the	 patient	 or	 the	 Bw4,	 C1	 and	 C2	
epitopes	present	in	the	donor.		
Although	 the	 data	 supporting	 donor	 KIR	 B	 haplotype	 and/or	 B	 motif	 together	 with	
patient	KIR	ligand	HLA-C	epitope	having	an	impact	on	transplant	outcome	is	impressive,	





























The	 expression	 of	 HLA	 proteins	 can	 be	 reduced	 within	 tumours	 due	 to	 deletion	 or	








Homozygosity	 and	 novel	 HLA	 alleles	 identified	 within	 DNA	 extracted	 from	 patients	






undertake	both	 straight-forward	and	 complex	donor	 selection.	GIAS	may	be	delivered	
from	an	H&I	laboratory	supporting	the	transplant	centre;	from	a	donor	registry	or	from	
within	 the	 transplant	 team.	 Key	 to	 the	 successful	 selection	 of	 optimum	 donors	 from	
related	 and	 unrelated	 sources	 is	 expert	 knowledge	 of	 the	 HLA	 system	 including:	
polymorphism,	 linkage	 disequilibrium,	 impact	 of	 recombination,	 ethnic	 variation	 and	




H&I	 scientists	 who	 have	 completed	 the	 British	 Society	 for	 Histocompatibility	 and	
Immunogenetics	 (BSHI)	 diploma	 and	 are	 Health	 and	 Care	 Professions	 Council	 (HCPC)	
registered	 will	 have	 achieved	 an	 adequate	 level	 of	 education	 to	 enable	 active	





























Bone	Marrow	Donors	Worldwide,	 http://bmdw.org,	 is	 the	 continuing	 effort	 to	 collect	







IPD-IMGT/HLA	 Database	 permits	 access	 to	 HLA	 DNA	 and	 protein	 sequences,	
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